The diagnostic values of C-reactive protein and procalcitonin in identifying systemic lupus erythematosus infection and disease activity
- PMID: 31415387
- PMCID: PMC6831178
- DOI: 10.1097/MD.0000000000016798
The diagnostic values of C-reactive protein and procalcitonin in identifying systemic lupus erythematosus infection and disease activity
Abstract
To explore the values of C-reactive protein (CRP) and procalcitonin (PCT) in identifying infection and disease activity in systemic lupus erythematosus (SLE) patients.Patients with SLE and infection from April 2015 to January 2018 were included in this study. We compared the clinical characteristics and biomarkers between different groups and calculated the receiver operating characteristic curve, sensitivity, and specificity of the corresponding biomarkers. Logistic regression analysis was performed on the variables exhibiting significant differences in univariate analysis.A total of 177 SLE patients were retrospectively analyzed. The patients were divided into noninfected-inactive group, noninfected-active group, infected-inactive group, and infected-active group. CRP level of infected-inactive group was significantly higher than noninfected-inactive group (P < .05), but not significantly in infected-active group than noninfected-active group (P > .05). Multivariate analysis showed that CRP (>24.0 mg/L) was the only independent risk factor for SLE infection (odds ratio, OR = 2.896, P = .032). PCT level of infected-active group was significantly higher than infected-inactive group (P < .05), but not significantly in noninfected-active group than noninfected-inactive group (P > .05). SLE active group had shorter disease course, lower infection rate, higher PCT level, and lower platelet count (PLT). Multivariate logistic analysis showed that PCT (>0.048 ng/mL) and PLT (<150 × 10/L) were independent risk factors for SLE activity (OR = 3.498 and 4.391, P = .011 and 0.009), and disease course (>96 months) was independent protective factor (OR = 0.169, P < .001). The area under the curve of the logistic model was significantly larger than any single variable (all P < .05).CRP is the only effective marker for diagnosing infection in SLE patients. Moreover, PCT helps predict SLE activity.
Conflict of interest statement
All authors declare that there is no conflict of interest and financial interest.
Figures




Similar articles
-
Serum procalcitonin and C-reactive protein levels as diagnostic markers for distinguishing bacterial infections from lupus flares in systemic lupus erythematosus: A systematic review and meta‑analysis.Int Immunopharmacol. 2021 Dec;101(Pt B):108304. doi: 10.1016/j.intimp.2021.108304. Epub 2021 Oct 30. Int Immunopharmacol. 2021. PMID: 34731783
-
Procalcitonin and C-reactive protein as markers of infection in systemic lupus erythematosus: the controversy continues.Lupus. 2019 Oct;28(11):1329-1336. doi: 10.1177/0961203318777101. Epub 2018 May 19. Lupus. 2019. PMID: 29779437
-
Serum procalcitonin and C-reactive protein for differentiating bacterial infection from disease activity in patients with systemic lupus erythematosus.Mod Rheumatol. 2014 May;24(3):457-63. doi: 10.3109/14397595.2013.844391. Epub 2013 Oct 21. Mod Rheumatol. 2014. PMID: 24252006
-
Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus.Lupus. 2012 Oct;21(11):1172-7. doi: 10.1177/0961203312450085. Epub 2012 May 30. Lupus. 2012. PMID: 22652631
-
The utility of erythrocyte sedimentation rate, C-reactive protein, and procalcitonin in detecting infections in patients with systemic lupus erythematosus: A systematic review.Lupus. 2022 Sep;31(10):1163-1174. doi: 10.1177/09612033221106157. Epub 2022 Jun 1. Lupus. 2022. PMID: 35650026
Cited by
-
Serum Amyloid A: A Potential Biomarker Assessing Disease Activity in Systemic Lupus Erythematosus.Med Sci Monit. 2020 Jun 25;26:e923290. doi: 10.12659/MSM.923290. Med Sci Monit. 2020. PMID: 32584794 Free PMC article.
-
Epidemiology, Clinical Data, and Management of Aseptic Abscess Syndrome: Review of Published Cases Outside France.Epidemiologia (Basel). 2025 Aug 7;6(3):44. doi: 10.3390/epidemiologia6030044. Epidemiologia (Basel). 2025. PMID: 40843703 Free PMC article. Review.
-
Development of Prediction Models for New Integrated Models and a Bioscore System to Identify Bacterial Infections in Systemic Lupus Erythematosus.Front Cell Infect Microbiol. 2021 Mar 1;11:620372. doi: 10.3389/fcimb.2021.620372. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 33732661 Free PMC article.
-
The effects of curcumin supplementation on inflammatory markers in systemic lupus erythematosus patients: a randomized placebo-controlled trial.Eur J Nutr. 2024 Nov 15;64(1):8. doi: 10.1007/s00394-024-03515-7. Eur J Nutr. 2024. PMID: 39546036 Clinical Trial.
-
A Challenging Diagnosis of Febrile Pancytopenia in a Patient With a History of Autoimmune Disease.Cureus. 2023 Mar 9;15(3):e35956. doi: 10.7759/cureus.35956. eCollection 2023 Mar. Cureus. 2023. PMID: 37038578 Free PMC article.
References
-
- Rua-Figueroa I, Lopez-Longo J, Galindo-Izquierdo M, et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum 2017;47:38–45. - PubMed
-
- Fors Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep 2016;18:21. - PubMed
-
- Barber C, Gold WL, Fortin PR. Infections in the lupus patient: perspectives on prevention. Curr Opin Rheumatol 2011;23:358–65. - PubMed
-
- Bouza E, Moya JG, Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001;15:335–61. - PubMed
-
- Mok CC, Lee KW, Ho CT, et al. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford, England) 2000;39:399–406. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous